within Pharmacolibrary.Drugs.ATC.N;

model N05AD07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AD07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Benperidol is a highly potent antipsychotic drug belonging to the butyrophenone chemical class. It acts primarily as a dopamine D2 receptor antagonist. It was used primarily for the treatment of schizophrenia and other psychotic disorders, but its use has become rare due to the availability of other antipsychotics. Benperidol is not widely approved or in clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on reported data for similar butyrophenone antipsychotics; no published clinical pharmacokinetic study in humans for benperidol was found.</p><h4>References</h4><ol><li><p>Seiler, W, et al., &amp; Hiemke, C (1994). Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. <i>Psychopharmacology</i> 116(4) 457–463. DOI:<a href=\"https://doi.org/10.1007/BF02247478\">10.1007/BF02247478</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7701049/\">https://pubmed.ncbi.nlm.nih.gov/7701049</a></p></li><li><p>Furlanut, M, et al., &amp; Forgione, A (1988). Pharmacokinetics of benperidol in volunteers after oral administration. <i>International journal of clinical pharmacology research</i> 8(1) 13–16. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3366499/\">https://pubmed.ncbi.nlm.nih.gov/3366499</a></p></li><li><p>Kumar, S, et al., &amp; Kumar, S (2017). In silico repurposing of antipsychotic drugs for Alzheimer&#x27;s disease. <i>BMC neuroscience</i> 18(1) 76–None. DOI:<a href=\"https://doi.org/10.1186/s12868-017-0394-8\">10.1186/s12868-017-0394-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29078760/\">https://pubmed.ncbi.nlm.nih.gov/29078760</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AD07;
